In a significant stride towards advancing cancer care, Makati Medical Center (MakatiMed) forges a collaboration with Roche Philippines, Inc. to introduce Comprehensive Genomic Profiling services.
Cancer screening, diagnosis, and treatment have always been paramount focuses at MakatiMed, with the Section of Oncology and the Cancer Center leading the charge. This partnership with Roche Philippines, Inc. underscores MakatiMed’s commitment to staying at the forefront of medical innovation and delivering cutting-edge solutions to patients.
Comprehensive Genomic Profiling represents a groundbreaking approach in cancer treatment by analyzing tumor genomes to identify clinically relevant alterations and signatures. By doing so, it opens up a spectrum of potential treatment options for patients, personalized to their specific genetic makeup.
The Memorandum of Agreement, signed on March 7, 2024 by esteemed figures including Diana Edralin, MD, President of Roche Philippines, Inc., Saturnino P. Javier, MD, MakatiMed Medical Director and Interim Co-President and CEO, and Arnold C. Ocampo, MakatiMed Chief Finance Officer and Interim Co-President and CEO), marks the beginning of this transformative collaboration.
Dr. Javier expressed his enthusiasm about the partnership, stating, “The collaboration paves the way for Comprehensive Genomic Profiling which analyzes tumor genome to identify clinically relevant alterations and signatures and thus potentially expand the patients’ treatment options.”
The introduction of Comprehensive Genomic Profiling services at MakatiMed reaffirms its position as a leading institution in healthcare innovation and patient-centered care. With this partnership, the institution continues to set the standard for excellence in cancer treatment, providing hope and healing to patients and their families.
